Neo Ivy Capital Management Has $689,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Neo Ivy Capital Management lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 371.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,528 shares of the medical equipment provider's stock after purchasing an additional 5,144 shares during the quarter. Neo Ivy Capital Management's holdings in Zimmer Biomet were worth $689,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ZBH. Roman Butler Fullerton & Co. acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth about $473,000. KLCM Advisors Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $7,825,000. Van ECK Associates Corp raised its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after purchasing an additional 218,688 shares during the last quarter. MFG Wealth Management Inc. acquired a new position in Zimmer Biomet during the fourth quarter worth $1,506,000. Finally, Gries Financial LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at $866,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZBH shares. Barclays cut their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Raymond James reduced their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Robert W. Baird lowered their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $111.53.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is owned by insiders.

Zimmer Biomet Trading Up 1.6%

Shares of NYSE ZBH traded up $1.52 during trading on Tuesday, reaching $94.16. The stock had a trading volume of 3,885,556 shares, compared to its average volume of 1,797,983. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $117.45. The company has a market cap of $18.63 billion, a P/E ratio of 21.16, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business's 50-day moving average price is $101.44 and its 200-day moving average price is $105.20.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.94 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.02%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.